ZN-d5 ZN-c3 + ZN-c3
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML)
Trial Timeline
Dec 1, 2022 → Jul 26, 2024
NCT ID
NCT05682170About ZN-d5 ZN-c3 + ZN-c3
ZN-d5 ZN-c3 + ZN-c3 is a phase 1/2 stage product being developed by Zentalis Pharmaceuticals for Acute Myeloid Leukemia (AML). The current trial status is terminated. This product is registered under clinical trial identifier NCT05682170. Target conditions include Acute Myeloid Leukemia (AML).
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05682170 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)